2008 Clinical Practice Guidelines - Canadian Diabetes Association

2008 CLINICAL PRACTICE GUIDELINES
S106
Management of Acute Coronary Syndromes, p. S119
Treatment of Diabetes in People With Heart Failure, p. S123
REFERENCES
1. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention
and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med. 2003;348:383-393.
2. Gaede P, Lund-Andersen H, Parving H, et al. Effect of a multifactorial
intervention on mortality in type 2 diabetes. N Engl
J Med. 2008;358:580-591.
3. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in
high-risk patients.The Heart Outcomes Prevention Evaluation
Study Investigators. N Engl J Med. 2000;342:145-153.
4. The Heart Outcomes Prevention Evaluation Study
Investigators. Effects of ramipril on cardiovascular and
microvascular outcomes in people with diabetes mellitus:
results of the HOPE study and MICRO-HOPE substudy.
Lancet. 2000;355:253-259.
5. Fox KM; EURopean trial On reduction of cardiac events with
Perindopril in stable coronary Artery disease Investigators.
Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease: randomised,
double-blind, placebo-controlled, multicentre trial
(the EUROPA study). Lancet. 2003;362:782-788.
6. Daly CA, Fox KM, Remme WJ, et al; EUROPA Investigators.
The effect of perindopril on cardiovascular morbidity and
mortality in patients with diabetes in the EUROPA study:
results from the PERSUADE substudy. Eur Heart J. 2005;26:
1369-1378.
7. Braunwald E, Domanski W, Fowler SE, et al; PEACE
Investigators. Angiotensin-converting-enzyme inhibition in stable
coronary artery disease. N Engl J Med. 2004;351:2058-2068.
8. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-convertingenzyme
inhibitors in stable vascular disease without left ventricular
systolic dysfunction or heart failure: a combined
analysis of three trials. Lancet. 2006;368:581-588.
9. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting
enzyme inhibitors in patients with coronary artery disease
and absence of heart failure or left ventricular systolic
dysfunction: an overview of long-term randomized controlled
trials. Arch Intern Med. 2006;166:787-796.
10. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting
enzyme inhibitors and calcium channel blockers for coronary
heart disease and stroke prevention. Hypertension. 2005;
46:386-392.
11. Poole-Wilson PA, Lubsen J, Kirwan BA, et al;A Coronary disease
Trial Investigating Outcome with Nifedipine gastrointestinal
therapeutic system investigators. Effect of long-acting
nifedipine on mortality and cardiovascular morbidity in
patients with stable angina requiring treatment (ACTION
trial): randomised controlled trial. Lancet. 2004;364:849-857.
12. The ONTARGET Investigators.Telmisartan, ramipril, or both
in patients at high risk for vascular events. N Engl J Med. 2008;
385;15:1547-1559.
13. DiMinno G, Silver MJ, Cerbone AM, et al.Trial of repeated lowdose
aspirin in diabetic angiopathy. Blood. 1986;68:886-891.
14. Halushka PV, Rogers RC, Loadholt CB, et al. Increased platelet
thromboxane synthesis in diabetes mellitus. J Lab Clin Med.
1981;97:87-96.
15. Davi G, Catalano I, Averna M, et al.Thromboxane biosynthesis
and platelet function in type II diabetes mellitus. N Engl J
Med. 1990;322:1769-1774.
16. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of
platelets from type 2 diabetic patients to acetylsalicylic acid
(aspirin) — its relation to metabolic control. Thromb Res.2004;
113:101-113.
17. Friend M, Vucenik I, Miller M. Platelet responsiveness to
aspirin in patients with hyperlipidaemia. BMJ. 2003;326:82-
83.
18. Final report on the aspirin component of the ongoing
Physicians’ Health Study. Steering Committee of the
Physicians’ Health Study Research Group. N Engl J Med. 1989;
321:129-135.
19. Sacco M, Pellegrini F, Roncaglioni MC, et al; PPP
Collaborative Group. Primary prevention of cardiovascular
events with low-dose aspirin and vitamin E in type 2 diabetic
patients: results of the Primary Prevention Project (PPP) trial.
Diabetes Care. 2003;26:3264-3272.
20. Hansson L, Zanchetti Al, Carruthers SG, et al. Effects of intensive
blood-pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension
Optimal Treatment (HOT) randomized trial. HOT Study
Group. Lancet. 1998;351:1755-1762.
21. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis
of randomised trials of antiplatelet therapy for prevention
of death, myocardial infarction and stroke in high risk
patients. BMJ. 2002;324:71-86.
22. Aspirin effects on mortality and morbidity in patients with diabetes
mellitus. Early Treatment Diabetic Retinopathy Study
report 14. ETDRS Investigators. JAMA. 1992;268:1292-1300.
23. Bhatt D, Marso S, Hirsch A, et al. Amplified benefit of clopidogrel
versus aspirin in patients with diabetes mellitus. Am J
Cardiol. 2002;90:625-628.
24. CHARISMA Investigators. Clopidogrel and aspirin versus
aspirin alone for the prevention of atherothrombotic events.
N Engl J Med. 2006;354;16.